Personalized HPV Risk Management and Prevention System

A next-generation system for reducing the incidence and prevalence of human papilloma virus (HPV) and related diseases, leveraging machine learning, bacteriophage therapy, wearable devices, personalized vaccines, and multi-omics data to provide targeted interventions and improve cervical health.

The original patent addressed the need for reducing HPV incidence and prevalence, but its method relied on a copper-based device with limited effectiveness. The new inventive concept tackles the limitations of the original patent by introducing a personalized and multi-faceted approach, integrating advanced technologies to provide a more comprehensive and effective solution.

The system comprises a machine learning module trained on a dataset of HPV-related genomic and microbiome data, generating a personalized HPV risk profile. A recommendation engine provides tailored prophylactic and therapeutic interventions based on the risk profile. The system also incorporates a copper-based device with bacteriophage therapy, targeting specific HPV-related bacterial strains to modulate the cervical microbiome. A wearable device with a nanosensor array detects changes in cervical mucus, providing real-time monitoring of HPV-related biomarkers. A personalized vaccine platform utilizes mRNA-based vaccines encoding for multiple HPV-related antigens, delivered via a microfluidic device to the cervical mucosa. Finally, a system predicting HPV-related disease progression combines machine learning algorithms with multi-omics data, providing a personalized risk assessment and recommending targeted therapeutic interventions.

The new claims introduce a paradigm shift in HPV risk management by integrating machine learning, bacteriophage therapy, wearable devices, personalized vaccines, and multi-omics data. The inventive concept's novelty lies in its ability to provide personalized and targeted interventions, addressing the limitations of the original patent's copper-based device.

Alternative embodiments of the system could include the use of different machine learning algorithms, varying bacteriophage therapy regimens, or incorporating additional wearable devices for monitoring other health parameters. Variations of the personalized vaccine platform could involve different mRNA-based vaccine formulations or delivery methods.

The Personalized HPV Risk Management and Prevention System has significant commercial potential in the healthcare industry, particularly in the fields of gynecology, oncology, and infectious disease prevention. The system's ability to provide targeted interventions and improve cervical health could lead to widespread adoption in clinical settings, with potential markets including hospitals, clinics, and research institutions.